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Abstract
New high-throughput, population-based methods and next-generation sequencing capabilities hold great promise in the
quest for common and rare variant discovery and in the search for ’’missing heritability.’’ However, the optimal analytic
strategies for approaching such data are still actively debated, representing the latest rate-limiting step in genetic progress.
Since it is likely a majority of common variants of modest effect have been identified through the application of tagSNP-
based microarray platforms (i.e., GWAS), alternative approaches robust to detection of low-frequency (1–5% MAF) and rare
(,1%) variants are of great importance. Of direct relevance, we have available an accumulated wealth of linkage data
collected through traditional genetic methods over several decades, the full value of which has not been exhausted. To that
end, we compare results from two different linkage meta-analysis methods—GSMA and MSP—applied to the same set of 13
bipolar disorder and 16 schizophrenia GWLS datasets. Interestingly, we find that the two methods implicate distinct, largely
non-overlapping, genomic regions. Furthermore, based on the statistical methods themselves and our contextualization of
these results within the larger genetic literatures, our findings suggest, for each disorder, distinct genetic architectures may
reside within disparate genomic regions. Thus, comparative linkage meta-analysis (CLMA) may be used to optimize low-
frequency and rare variant discovery in the modern genomic era.
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Introduction
The genetic architectures of many major neuropsychiatric
disorders remain unresolved despite decades of linkage, fine
mapping, genomewide linkage (GWLS), candidate gene associa-
tion and genomewide association studies (GWAS). This lack of
resolution is not due to categorical failures of any one of these
methods as many independent investigations of each type have
produced strong evidence of linkage or genetic association for
many neuropsychiatric disorders. Rather, the apparent breakdown
lies in the general lack of replication within and across methods.
Importantly, although replication is the cornerstone of scientific
validation, the lack of replication may be wholly consistent with
the underlying genetic architectures of neuropsychiatric disorders.
Each genetic method has known strengths and liabilities. Thus,
rather than serving as an impediment to progress, contradictory
results across studies and methods may offer valuable insights into
the genetic architecture of these disorders. Our investigation
focuses on bipolar disorder (BP) and schizophrenia (SCZ), which
have particular public health significance due to their high
heritability and prevalence, frequent treatment resistance and
morbidity.
A Note on Genetic Architecture
Thornton-Wells, et al (2004) [1] provide a critical conceptual
framework for studies aiming to address genetic architecture by
reviewing factors that contribute to the statistical difficulties of
studying complex genetic disorders, including: allelic heterogene-
ity, locus heterogeneity, trait heterogeneity, phenocopy, pheno-
typic variability, gene-gene interactions and gene-environment
interactions. They note that each of these factors complicates
statistical analyses in one of two ways: 1) by creating heteroge-
neous, or competing, disease models or 2) by creating a
multifactorial, interacting disease model. (The second model is
often referred to as a ‘polygenic’ model and this term will be used
hereafter.) Their definitions of allelic and locus heterogeneity and
of gene-gene-interactions, in particular, are most relevant to our
study.
The presence of allelic or locus heterogeneity creates heteroge-
neous disease models because two or more genetic variants (i.e., at
two or more alleles or genes, respectively) are independently
associated with the same trait in the affected population. By
contrast, the presence of gene-gene interactions creates a polygenic
model because two or more genetic variations interact directly or
indirectly, in the individual affected persons, to alter disease risk
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former refers, implicitly, to a population-level phenomenon while
the latter refers to individual-level phenomena. The authors are
careful to note that each model may be relevant to different subsets
of subjects affected by the same disorder and that these models are
not mutually exclusive. Finally, each model will have distinct
implications for the nature of the involved variants.
Heterogeneous Models. The degree of population-level
heterogeneity and the extent of individual-level polygenicity each
have implications for the expected frequencies and penetrances of
the pathogenic or susceptibility variants. The population
frequencies of pathogenic variants for a given disease will be
inversely proportional to the extent of heterogeneity in the
population. Under a model of robust genetic heterogeneity,
then, the frequency of any single variant (e.g., allele, CNV) in the
population will necessarily be low (i.e., will be a low-frequency or
rare variant). Furthermore, penetrances are expected to be higher
for low-frequency variants in order to give rise to a common
disease in the population. (If frequencies were low and penetrances
were weak, then the simultaneous expression of several rare
variants would be required for disease expression in each
individual and disease would necessarily be extremely rare.) The
lower the frequencies of each contributing pathogenic variant in
the population, the greater the number of variants necessary in the
population to mediate risk for a common disease. Thus, a disorder
dominated by a heterogeneous model is one in which many
relatively rare but more highly-penetrant pathogenic variants
mediate risk for the disease in the affected population.
Polygenic Model. The frequencies of pathogenic variants
will, on the other hand, be directly proportional to the extent of
polygenicity required for individual disease expression. Under a
common disease model of robust polygenicity, the frequencies of
the contributing variants in the population will need to be
relatively high in order to fulfill the necessity that each affected
individual carries multiple such variants. Furthermore, by virtue of
their persistence in the species, common variants are expected to
have low disease penetrances. Moreover, we expect that common
variants of large effect would have been identified and replicated
over previous decades of genetic investigation, including GWAS.
Therefore, a disorder dominated by a polygenic model will be one
in which several common variants of modest effect contribute to
risk for disease in each affected individual.
A Brief Comparison of Genetic Methods
Genetic Association. Genetic association studies, by design,
select polymorphic markers within candidate genes or regions and
measure the extent of allelic association with disease at those
markers within a case-control or family-based design. GWAS, a
much larger-scale design, agnostic with regard to candidate genes
or regions, uses hundreds of thousands of tag SNPs to identify
relatively small regions (tens of thousands of basepairs) likely to
harbor susceptibility variants. By using common SNPs, GWAS are
optimized for detection of common disease-associated alleles of
modest effect.
Linkage Analysis. By contrast, linkage studies are family-
based studies that measure the cosegregation of trait loci with
genetic markers within each family. Genome-wide linkage studies
(GWLS), by extension, use a large set (hundreds to thousands) of
relatively evenly spaced DNA markers across the genome to detect
broad regions (millions of base pairs) likely to harbor disease
susceptibility loci, based on the pattern of within-family
correlations between marker alleles and disease. Linkage analysis
is most robust to the detection of regions harboring loci of large
effect or regional clusters of uncommon/rare risk-associated loci
[2,3]. That said, the extent to which linkage analysis will produce
consistent evidence of linkage across GWLS depends upon the
underlying architecture of the disorder. Under a rare or private
functional variant model with extensive locus heterogeneity,
linkage evidence will (by definition) be modest and generally
inconsistent [4,5]).
Relative Power
Current GWAS are optimally powered to find variants
conferring relative risks of .1.1. However, as GWAS are
conducted using commercial genotyping arrays designed to tag
common variants, these studies are underpowered to identify low
frequency risk variants even if these variants confer large (2.0)
relative risks [6]. By contrast, linkage analysis is not sufficiently
powered to identify alleles conferring small relative risk (i.e., 1.1–
1.5) [6,7]. However, when odds ratios at individual loci are $3, or
there are many independent risk variants, linkage is more powerful
than association [7].
Summary of Previously Published GWAS Findings
To date, there have been 12 published GWAS
[8,9,10,11,12,13,14,15,16,17,18,19] and two GWAS meta-analy-
ses [20,21] that included subjects with bipolar disorder and 13
GWAS [9,22,23,24,25,26,27,28,29,30,31,32,33] and 3 GWAS
meta-analysis [21,29,31] that included schizophrenic subjects.
Some of these studies included mixtures of subjects with bipolar
disorder, schizophrenia and/or major depressive disorder
[9,13,20,21].
Thus far, two independent, primary GWAS in bipolar disorder
have each reported one SNP association exceeding genomewide
(GW) significance (i.e., after multiple hypothesis testing correc-
tions). First, Baum, et al [8] found GW association evidence for
rs1012053, within the DGKH gene, yielding an association p-
value=1.50E-08, which exceeded a priori significance thresholds.
Second, the Wellcome Trust Case Control Consortium (WTCCC)
GWAS [14] reported association at rs420259, in the PALB2 gene,
with p=6.23E-08 exceeding the investigators’ a priori threshold of
p,5E-07. Though single marker results exceeding GW signifi-
cance thresholds are rare, and despite minimal apparent
convergence in suggestive findings across independent GWAS,
four GWAS meta-analyses in bipolar (or mixed samples) have
provided GW evidence for SNP association. Baum et al (2008)
[34] conducted a meta-analysis of 76 SNPs with individual
genotypes available from two bipolar studies [8,14] and identified
2 SNPs (rs10791345 in JAM3, p=1E-06; rs4806874 in SLC39A3,
p=5E-06) exceeding the study a priori GW significance threshold
(p,7E-05). Ferreira et al (2008) [11], performed a BP meta-
analysis combining their own BP sample with previously analyzed
[14,17] samples, identifying one SNP (rs10994336 in ANK3,
p=9.1E-09) that exceeded and one SNP (rs1705236 in CAC-
NA1C, p=7E-08) that nearly exceeded their GW threshold
(p,5E-08). Wang et al (2010) [21], performed a combined BP [18]
and SCZ [27,29,35] GWAS meta-analysis and produced 3 SNP
associations (rs11789399 and rs11789407, both flanking ASTN2
gene, p=5.56E-09 and p=1.55E-08, respectively; and
rs12201676, between GABRR1 and GABBR2 genes, p=3.88E-
08) exceeding their GW significance threshold (p,7.20E-08).
Finally, Liu et al (2011) [20] performed a combined BP [14,17]
and MDD [36] GWAS meta-analysis, which identified two SNPs
(rs1006737 and rs7297582, both in CACNA1C gene, p=3.1E-08
and p=3.4E-08, respectively) exceeding GW significance thresh-
old (p,5E-08).
In schizophrenia, one primary GWAS [27] has reported a SNP
association (rs1344706 in ZNF804A, p=1.61E-07) exceeding the
Meta-Analysis and Genetic Architectures
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addition to the combined BP and SCZ meta-analysis by Wang,
et al [21] described above, three additional GWAS meta-analyses
incorporating schizophrenic GWAS samples have produced SNP-
level findings exceeding GW significance. First, Shi et al (2009)
[29], performed a meta-analysis of 3 independent SCZ GWAS
samples [29,31,37] and identified 7 GW significant SNPs spanning
209 kb on 6p22.1, and in strong LD, that contains several genes of
potential biological significance. The authors could not ascertain
whether the signal in this large region was driven by one or several
genes, intergenic elements or by longer haplotypes that include
susceptibility alleles in many genes. Second, Stefansson et al (2009)
[31] performed an extended follow-up analysis to their primary
GWAS (GWAS+FU) and a meta-analysis (Meta) combining results
across 4 samples, finding 3 and 4 GW significant (p .1.6E-07)
SNPs, respectively. Of the 7 markers attaining GW significance in
either analysis, 5 (rs6913660, rs13219354, rs6932590, rs13211507,
rs3131296) were located within the extended MHC region on 6p
(within/near HIST1H2BJ, PRSS16, PRSS16, PGBD1, NOTCH4
genes, respectively), one (rs12807809) was 3457 bp upstream of
NRGN and the other (rs9960767) was within the TCF4 gene.
Finally, Athanasiu et al (2010) [22] performed a GWAS, an
independent replication analysis of their top 1000 GWAS markers
in another sample [38], and a combined analysis of the primary and
replication samples. Their replication study produced one GW
significant (a priori threshold, p,0.00024) SNP (rs7045881)
association in the PLAA gene (p=1.96E-04). Their combined
analysis produced three GW significant (p,5E-05) SNP
(rs7045881, rs433598, rs10761482) associations in PLAA
(p=2.2E-06), ACSM1 (p=3.27E-06) and ANK3 (p=7.68E-06),
respectively.
In summary, then, there are several important points regarding
extant bipolar and schizophrenia GWAS. First, primary GWAS in
each disease have produced very few GW significant SNP findings
(2 in bipolar, 1 in schizophrenia). Second, while GWAS meta-
analyses in each disease have identified SNPs (8 in bipolar, 20 in
schizophrenia) reaching GW significance thresholds in/near a
handful of genes (6 genes in bipolar, 11 in schizophrenia), no two
meta-analyses in a single disorder have found the same SNP (nor
two SNPs within the same gene) to exceed GW significance
threshold. Third, two different SNPs within the ANK3 gene
(rs10994336- Ferreira et al, 2008 and rs10761482-Athanasiu et al,
2010) have produced GW significant meta-analytic evidence of
association with bipolar disorder and schizophrenia, respectively.
Fourth, two SNPs in the CACNA1C gene (rs1006737 and
rs7297582) reached GW significance in a combined bipolar and
MDD meta-analysis [20], one of which (rs1006737) surpassed GW
significance, but only in the expanded reference group analysis by
Ferreira et al (2008) [11].
Thus, while a small number of common variants have shown
evidence for genetic association with bipolar disorder and/or
schizophrenia, the vast majority of the heritability for these
disorders remains unexplained by GWAS studies to date.
Therefore, we suggest that extant linkage data may be an
untapped and cost-efficient source of valuable information about
the regional genomic architecture of low-frequency and rare
variants underlying complex disorders.
Challenges Facing Linkage Analysis
With that said, we are still left with the problem of evaluating
and interpreting linkage findings in the context of the unresolved,
but certainly complex, genetic architectures of neuropsychiatric
disease. Generally speaking, linkage studies present two funda-
mental statistical barriers to replication: 1) high dimensionality
relative to sample size, which may result in a significant number of
false positive results and insufficient power, and 2) small effect size,
likely due to a disease being caused by multiple mutations in
different regions, across or within families (i.e, allelic or locus
heterogeneity) [39,40,41]. For complex genetic diseases in
particular, these problems lead to generally low linkage scores
and poor agreement between different linkage studies. One
approach to this problem is to use meta-analytic methods to
combine the data from multiple studies. A well-constructed meta-
analysis objectively integrates the results between studies, increas-
ing power when the results are in agreement with each other
[40,41,42,43].
Study Objectives: Comparative Linkage Meta-Analysis &
Examination of Architectural Implications
Here we look at two meta-analytic methods: Badner and
Gershon’s multiple scan probability (MSP) method [41,44] and
the genome scan meta-analysis (GSMA) method [40,45,46]. MSP
is known to have higher power to detect large effects that may
have high variance (i.e., it is more dependent on effect size), while
GSMA has higher power to detect effects with small variance (i.e.,
is more dependent on consistency of results) across independent
studies [43]. A previous review of meta-analytic results derived
across these methods [5] found modest consistency of results for
schizophrenia and an absence of replication for bipolar, and
discrepant results were attributed to differences in the datasets
being analyzed by the two methods. We were interested in identifying
differences in results produced by these two methods using the same set of data
as we believe that such differences may be especially useful in untangling the
genetic architectures of these complex disorders. The primary objectives of
our investigation, rather than to complete comprehensive meta-
analyses for these disorders, were 1) to compare the meta-analytic
findings obtained under two different methods using results from
the most recent published GWLS, and 2) to examine the potential
implications of convergent and discrepant results for the
underlying genetic architectures of bipolar disorder and schizo-
phrenia given other genetic evidence (e.g., GWAS) available for
these disorders.
Extrapolating from its methodologic strengths and weaknesses,
we expect that MSP will identify relatively strong effect loci that
are likely relevant to a smaller number of affected individuals. As
such, we expect MSP to implicate regions likely to harbor a genetic
architecture most befitting models of genetic heterogeneity. This
implication should be strongest for regions in which MSP, alone,
finds significant evidence of linkage.
GSMA, by contrast, is expected to identify genomic regions that
most consistently harbor one or more loci related to disease across
the included GWLS. Importantly, then, GSMA may implicate a
region via two different mechanisms, either 1) the same locus is
responsible for the region’s significance or 2) separate disease-
linked, low-frequency loci co-localize to the same region across
GWLS samples (heretofore referred to as the single locus vs.
multiple loci mechanisms, respectively). If the single locus
mechanism pertains, the implicated locus will necessarily be
reasonably common and, thus, be more likely to mediate smaller
(i.e., modest to moderate) effects. In this case, significant GSMA
findings are most likely to implicate polygenic models. If the
multiple loci mechanism pertains, then the convergence of several
distinct loci would have been necessary to produce regional
significance, and thus, each implicated locus will be of relatively
low-frequency in the sampled families and more likely of moderate
to larger effect. Under the multiple loci mechanism, significant
GSMA findings may be more consistent with heterogeneous
models of genetic architecture. Co-localization of MSP and/or
Meta-Analysis and Genetic Architectures
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relative likelihood of the two mechanisms (see Discussion).
Hypotheses
While full testing of our more specific architectural hypotheses
must await sequencing and functional investigations of genes
within these regions, examining our results in light of extant
genetic literature may provide additional evidence (for or against)
these hypotheses. If the two meta-analytic methods are truly
implicating regions with distinct architectures, we expect to find: 1)
little overlap between GSMA and MSP findings for either disease;
2) relatively more agreement between the regions implicated by
GWAS and those implicated by GSMA (as opposed to by MSP),
particularly if the GSMA significance derives from the single locus
mechanism. That said, there are caveats to the standard
interpretation of GWAS that provide for an alternative expecta-
tion of agreement between GWAS and MSP findings. As will be
elaborated in the Discussion, we also expect 3) more agreement
between MSP and GWAS when regional clustering of rare
variants creates synthetic association signals at GWAS SNP
markers.
Materials And Methods
Data Collection
Given our comparative objectives, studies included were limited
to English-language GWLS of bipolar disorder and schizophrenia
catalogued in PubMed and published between 2000 and 2010.
Relevant articles were obtained by searching PubMed and from
the relevant references cited by authors of previous meta-analyses.
(See File S1 for more detailed description of data collection,
literature search screening procedures, comparison of included
studies to previous GWLS meta-analyses, ethnic composition of
original GWLS, marker mapping and inclusion procedures, data
preprocessing, and procedures for handling missing marker data).
Multiple-Scan Probability (MSP)
In this study we apply and contrast the results of two different
methods of combining linkage studies. The first method, MSP,
developed by Badner and Gershon [41,44], modifies Fisher’s
method [47]. Fisher’s method combines p-values from multiple
tests about the same hypothesis to obtain a single test statistic:
Y2 ~{ 2
Xk
i~1 ln (pi) ð1Þ
Y
2 has a chi-square distribution (with degrees of freedom equal to
twice the number of studies) under the null hypothesis and
therefore yields an overall p-value that incorporates information
from each individual test. When using the MSP method, this value
is referred to, simply, as the MSP. Large p-values do not
contribute significantly to the sum and inflate the number of
degrees of freedom of the chi-square distribution, therefore
increasing the MSP. As such, Fisher’s method is conservative in
that it takes into account evidence both for and against the null
hypothesis by design. However, Fisher’s method cannot be directly
applied to linkage studies, because linkage evidence is often
observed for broad regions and not single points [41]. This occurs
as a result of association between loci which are close together on
the chromosome and because studies may use different marker
sets.
The modification used by MSP allows for the analysis of linkage
regions by accounting (correcting) for the effects of crossover,
marker spacing, family structure and original linkage methods
used. After all original GWLS results are assembled, ‘corrected’ p-
values (p*) are derived from each original p-value:
p   ~Cpz2lGZ(p)Q(Z(p)) v ½Z(p) sqrt(4lD) ð 2Þ
p is the raw p-value, C is the number of chromosomes spanned by
the region (in this case, all regions are on a single chromosome), l
is the crossover rate per Morgan, G is the region size in Morgans,
Z(.) is the standard normal inverse, w(.) is the normal density, and
D is the marker spacing in Morgans. Next, candidate regions are
identified by searching for markers with a p-value below a fixed
threshold in at least one original study. Once such a marker is
identified, a ‘window’ of pre-determined length is opened around
that marker. The minimum observed p* falling within that
window for each study is then included in the MSP calculation:
MSP~P(x2 with2kdegreesof freedomwY2) ð3Þ
by substituting p* for pi in Equation 1. In this study, for the size of
the linkage window and p-value threshold, we use values of 30 cM
(615 cM from triggering marker) and 0.01, respectively, following
the example of Badner and Gershon (2002) [41].
Several studies utilize multiple diagnostic models. For example,
a study of bipolar disorder may yield one set of linkage scores by
counting only patients with bipolar I disorder as affected (narrow
model), and another by counting patients with either bipolar I
disorder or bipolar II disorder (broad model). This can be dealt
with in MSP either by analyzing only the results based on the
broadest diagnostic model used in the study (MSP-Single) or by
incorporating only the most significant model’s p-value and
including a penalty for multiple testing (MSP-Best). We elected to
complete the MSP analysis using both the MSP-Single and MSP-
Best approaches in order to also evaluate and compare the results
obtained with each.
It is theoretically possible for MSP to find significance because
evidence for linkage was present in only one of the included
studies. However, even if this is the case, the conservative design of
the method allows it to provide more robust statistical evidence of
linkage than that provided by the original GWLS. Discrepant
linkage evidence between studies does not necessarily invalidate a
finding as evidence for linkage can vary considerably depending
(among other factors) on the degree of genetic heterogeneity, the
proportion of parents homozygous for the susceptibility gene,
ethnic stratification within the pedigree sample and ascertainment
methods employed [41].
Genome Scan Meta-Analysis (GSMA)
The GSMA method for meta-analysis of linkage studies divides
each chromosome into segments of fixed length, called ’bins‘. In
this study, we use 30 cM bins, following Levinson et al [40]. For
each included study, bins are ranked based on the lowest p-value
among markers they contain, with the bin containing the lowest p-
value for that study attaining a rank of 1. Bins with tied p-values
are assigned the average of their ranks [40]. The rank of each bin
is summed across all studies, with studies weighted by sample size,
producing a summed-rank (SR) statistic and corresponding SR p-
value. Bins that consistently contain relatively low p-values will
have a low SR, so that the SR p-value is a measure of the
consistency of linkage evidence in that bin. Simulation studies
demonstrate that SR p-values have the standard interpretation of
type 1 error rate under the null hypothesis [40]. For comparability
to MSP results, we conducted both GSMA-Broad and GSMA-
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value obtained under the broadest diagnostic model employed in
each original GWLS was used for determining the rank of each
bin. For GSMA-Best, the best result, regardless of model, was used
to determine rank.
Because GSMA is rank-based, the magnitude of a detected
effect is used only to determine its rank, so that if a very large effect
is observed only rarely across studies within a particular bin,
GSMA will have low power to detect it. This can occur if strong
linkage is only found in a region for certain populations or pertains
to only one sub-phenotype. Since meta-analyses typically incor-
porate data from a variety of populations, it is possible to miss
regions of importance to only a segment of the affected population
when relying solely on GSMA. By design, GSMA will reliably fail
to implicate regions in which marker rank is highly variable across
[46] independent GWLS, prioritizing signal consistency over
signal intensity. Additionally, GSMA relies on pre-assigned bins,
and has reduced power to detect signals that fall near their
boundaries, as the effect may be split between two bins. Increasing
bin size may allow the effect to be captured in a single bin in
specific cases, but reduces overall power, as a consistent linkage
signal is unlikely to be found over a large region. For consistency,
we modified the GSMA bin definitions employed by Wise et al
(1999) [46] by remapping the start and end markers for each bin to
deCODE.
In contrast, MSP has higher power to detect such effects, but
may fail to detect small signals, even if they occur consistently. For
MSP, regions of potential interest are identified based on locations
of strong linkage signals from individual studies and not fixed in
advance.
Hypothesis Testing Corrections
In our results tables, we report all GSMA bins and MSP
windows for which nominally-significant results were obtained on
meta-analysis and indicate those results retaining significance after
conservative multiple testing corrections. For the GSMA analyses,
we applied standard Bonferroni corrections for 120 bins, following
the example of Levinson et al (2003) [40]. For the MSP analyses,
we employed the most widely-used conservative thresholds,
originally proposed by Lander and Kruglyak (1995) [48] (LK-
significant=2.2E-05, LK-suggestive=7.0E-04). Badner & Ger-
shon (2002) [41] tested these thresholds using simulations and
showed that they are conservative when using corrected
probabilities (p*) and nonzero window size.
Results
A total of 35 English-language GWLS published between 2000
and 2010 were identified through PubMed literature search.
Twenty-nine were included in disease-specific MSP and GSMA
analyses, including 13 for bipolar disorder [49,50,51,52,53,54,55,
56,57,58,59,60,61] and 16 for schizophrenia [62,63,64,65,66,67,
68,69,70,71,72,73,74,75,76,77] (See Table S1 & Table S2 for full
descriptions of included GWLS). The total number of studies
identified, number of studies included and corresponding number
of marker instances included in the meta-analyses are reported in
Table 1. Multiple marker instances may occur for a single marker
if the marker is used in more than one original study and/or is
used to test more than one disease model in a single study.
Results in Tables 2 and 3 display the chromosome region for the
MSP window or GSMA bin, linkage window midpoint marker
(MSP) or bin number (GSMA), results from MSP-Single, MSP-
Best, GSMA SR (narrow model) and GSMA SR (broad model) for
all windows/bins found to reach nominal significance threshold
(p=0.05) for bipolar (Table 2) and schizophrenia (Table 3)
analyses. The final column in each table contains a list of the
significant bipolar and schizophrenia GWAS findings, if any, for
that region as reported in the Catalog of Published Genome-Wide
Association Studies [78], accessed 11/17/10). Any MSP window
instances with the same start/end locations necessarily produce the
same results (because they are combining the same set of markers).
The set of windows with non-identical start/end locations are
referred to as ‘unique windows’ or, simply, ‘windows’ (as opposed
to ‘window instances’).
MSP Results
Bipolar Disorder. Of the original 4640 Bipolar GWLS
marker instances subjected to our meta-analyses, 18 window
instances, representing 16 unique windows, yielded at least
nominally-significant findings (p,0.05) in one or both MSP
meta-analysis (Table 2). Significant MSP results were found on 10
different chromosomes. A slightly greater number of windows
were significant under MSP-Best (16) than MSP-Single model (13)
and no windows were significant for MSP-Single (broad model)
only. Additionally, results for MSP-Best were consistently equal to
or more significant than results for MSP-Single, but in only one
case (8q24.13-q24.3) was the difference large.
The most significant MSP results for both MSP-single and
MSP-best (p=4.61E-08) was found at 5q14.3-q23.3. Two
additional windows retained significance under LK-significance
criteria for both MSP-Single and MSP-Best: 14q11.2-q13.1
(p=6.02E-08) and 5p13.3-q13.3 (p=3.63E-07). Finally, two
additional windows met LK-suggestive criteria under both models:
14q12-q22.3 (MSP-Single & MSP-Best p=1.41E-04) and 6p23-
p21.1 (MSP-Single p=4.68E-04, MSP-Best p=1.35E-04). Of the
16 nominally-significant MSP windows, 14 were MSP-only
windows. Nine of 14 (64%) significant MSP-only windows
contained 13 significant GWAS SNP and/or GWAS meta-
analysis associations [11,13,14,16,21]. Of the three unique MSP
windows meeting LK-significance criteria, the two most significant
contained seven SNP associations from four GWAS or GWAS
meta-analyses [11,13,16,21] (Table 2).
Schizophrenia. Of the original 12395 schizophrenia GWLS
marker instances subjected to meta-analyses, 22 window instances
(representing 16 unique windows) yielded nominally-significant
findings (p,0.05) on MSP-Best analysis. Significant MSP results
were found on 5 different chromosomes. In contrast to the bipolar
results, the schizophrenia MSP-Single results were dramatically
weaker than those for MSP-Best and no MSP-Single result
approached nominal significance (Table 3). The most significant
window on MSP-Best analysis was at 1q23.2-q25.3 (p=1.94E-03),
just under LK-suggestive criteria, providing nominal evidence for
linkage within the window. No schizophrenia window retained
significance under LK criterion. Of the 16 nominally-significant
MSP windows, 15 were MSP-only windows. Within seven of 15
(47%) MSP-only windows were three significant GWAS meta-
Table 1. GWLS Studies and Marker Counts Included in Meta-
analyses.
ss
Original
GWLS
Identified
Original
GWLS
Included
Marker Instances
from Included
GWLS
Bipolar Disorder 17 13 4640
Schizophrenia 18 16 12395
doi:10.1371/journal.pone.0019073.t001
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bipolar-schizophrenia meta-analysis by Wang, et al (2010) [21],
and there was no overlap with any primary schizophrenia GWAS
findings.
GSMA Results
While several bins reached a nominal significance threshold of
p,0.05 in each disorder, no bin’s significance survived Bonferroni
correction for 120 hypothesis tests in either disorder. That said, a
pair of adjacent bins in bipolar disorder (10.2 and 10.3) and 2 pairs
of adjacent bins in schizophrenia (3.4 and 3.5, 6.5 and 6.6) were
implicated by nominally significant GSMA findings. As demon-
strated by simulations conducted by Levinson, et al (2003) [5,40]
when adjacent clusters of bins meet GSMA significance criteria,
they are unlikely to represent false positives. Furthermore, since
the Bonferroni correction assumes complete independence of all
tests, it is conservative in the present context.
Bipolar Disorder. Six of 120 bins on 4 chromosomes
reached nominal significance in the bipolar GSMA analysis,
under one or both models. In contrast to the bipolar MSP results,
the GSMA-Broad results were consistently (though modestly) more
significant than the GSMA-narrow results. The most significant
bin under both broad (p=0.0060) and narrow (p=0.0099)
analyses was bin 3.2, spanning 3p25.3-3p22.1. The second most
significant bin under both broad (p=0.0127) and narrow
(p=0.0172) models was bin 10.2, spanning 10p14-q11.21.
Adjacent bin 10.3 (10q11.21-q22.1) was also nominally
significant. Of the 5 nominally-significant GSMA bins, 4 (80%)
were GSMA-only bins. Four of 4 (100%) significant GSMA-only
bins in bipolar analysis contained 10 unique GWAS SNP
associations (Table 2).
Schizophrenia. Seven of the 120 bins reached nominal
significance in the schizophrenia analysis. In contrast to the
bipolar GSMA results, some GSMA bins produced more
significant findings under the GSMA-broad (3 bins) model and
others under the GSMA-narrow model (4 bins). The most
significant bin under both broad (p=0.00267) and narrow
(p=0.011058) GSMA models was bin 6.6 at 6q25.3-qter. This is
adjacent to another bin significant under both models: 6.5 at
6q23.2-q25.3. Additionally, adjacent bins 3.5 (3q12.3-q22.1) and
3.4 (3p14.1-q12.3) are also both significant under the narrow
GSMA model. Of the 7 nominally-significant GSMA bins, 6
(85%) were GSMA-only bins. Only 2 of 6 (33%) GSMA-only bins
contained 3 nominally-significant SNP associations (all from [21]).
Additionally, the three bins within which these significant GWAS
SNPs resided were those in which the GSMA-broad model was
superior to the GSMA-narrow model.
MSP-GSMA Overlap
Bipolar Disorder. Of the twenty unique genomic regions
representing a significant window instance, bin or the overlap
thereof (Table 2), only two regions on chromosome 10 produced
partially-overlapping MSP-GSMA results. The 10p11.21-q22.1
MSP window is contained completely within the boundaries of two
GSMA bins (10.2 and 10.3). Notably, this region of MSP-GSMA
overlap in bipolar disorder contains the most highly-replicated
gene finding in bipolar disorder to date (see Discussion). A second,
nearby MSP window, 10q22.1-q24.1, also overlaps marginally
with GSMA bin 10.3 at band 10q22.1.
Schizophrenia. Of twenty-two unique genomic regions with
significant meta-analytic findings, only one region on chromosome
6 contained partially-overlapping nominally-significant MSP-
GSMA results. One MSP window (6q22.31-q24.3) overlapped
with a GSMA bin (6q23.2-q25.3), creating one distinct region of
MSP-GSMAoverlap:6q23.2-q24.3.Interestingly,noschizophrenia
GWAS has implicated this region, but a GWAS in a combined
bipolar and major depressive disorder sample implicated a SNP
within the non-overlapping portion of this GSMA bin (6q25.2,
rs17082664-G in SYNE1) [20].
For both disorders, the observed absence of MSP-GSMA
overlap among the significant results is further supported by the
fact that most significant findings under one method did not even
approach significance under the other method (See Table S3 &
Table S4 for further details.).
Discussion
Notably, 5 MSP windows retained significance after multiple
testing correction in the bipolar analysis. Additionally, nominally-
significant evidence for linkage was found in all primary analyses
in MSP and GSMA for both disorders and several sets of
adjacent bins were implicated in the GSMA analyses. The failure
of GSMA (in either disease) or of MSP (in schizophrenia) to
detect evidence of linkage that withstood multiple testing
corrections has several potential explanations. First, there may
be no true linkage for these disorders. While theoretically
possible, the accumulated evidence for heritability is strong, with
heritability estimates of approximately 80–85% [4,79], making
true absence of genetic linkage within families unlikely. Second,
linkage (and therefore linkage meta-analysis) failed to detect
robust signals because the majority of the actual contributory loci
are of modest effect. In this case, linkage studies would not the
method of choice for detection. We would also submit that this
explanation is unlikely; while modest effect variants certainly
contribute to disease susceptibility, if these were the sole
contributors, we would have expected much more robust findings
from studies designed especially to detect such a risk architecture
(i.e., GWAS).
A third potential explanation is that the substitution of neutral
p-values for missing data effectively drowned out more substantial
trends in the data that would have been apparent if all marker
information had been available. Thus, we would expect that the
inclusion of all marker information would, by and large, lead to
the preservation, and possible enhancement, of significance of the
bins implicated by our GSMA analysis. This expectation bore out
in our bipolar reduced (RED) post-hoc analysis wherein the
identical set of 6 bins was implicated as in the full analysis, with
only one change to the rank order (i.e., flipping of bins 7.4 and
12.4 between 3
rd and 4
th position). (See File S1 and Table S5 for
further details on Reduced Post-Hoc Analysis.) Similarly, we
expect that the inclusion of many neutral p-values in the MSP
calculations is also a conservative approximation of the distribu-
tion of p-values likely to reside within a window. The RED
analysis, again, demonstrated the neutralizing effect of removing
studies with missing data from the analysis.
Finally, failure of most results to withstand multiple testing
correction may also be the result of extensive genetic heteroge-
neity and contributions by rare variants in these disorders. If
disease risk is largely mediated by rare or private causative
variants, then individual linkage studies and conservative meta-
analytic approaches may fail to produce findings exceeding
standard significance thresholds, even in the presence of
substantial heritability and true linkage [4]. Under such a model,
only large, extended pedigrees with ‘Mendelian-like’ structures
(and statistical accounting for heterogeneity) may be capable of
producing robust linkage signals [80] (also see Baron, 2001 [81]
for an overview of the relative merits of various sample
characteristics and analytic approaches to linkage). This may,
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and by the inclusion of the Marcheco-Teruel study [57] which
was conducted using a very large, extended pedigree and
nonparametric methods that can account for intrafamilial
heterogeneity.
Pattern of Findings across Methods
Perhaps our most compelling finding is the unique distribution
of significant regions produced by each method for each disorder
(Tables 2 & 3). Given the number of MSP window-triggering
marker instances in the original GWLS (SCZ=133, BP=56, full
Table 2. Linkage Meta-Analyses Results for Bipolar Disorder.
p-values
ChrBAND for MSP
Window/GSMA Bin
Midpoint
Marker/
Bin # MSP single MSP best
GSMA
narrow
GSMA
broad
Schizophrenia (SCZ) and Bipolar Disorder (BP) GWAS Findings
Overlap
2p25.3-p25.1 rs726342 0.00564 0.00268
2p22.2-p13.3 rs195573 0.02377 0.00832 SCZ: 2p16.1 (VRK2): Stefansson - OR=1.09, p=3E-07
2p16.2-p11.2 rs1396798 0.01815 0.00348 BP: 2p12 (CTNNA2): Scott - OR=1.2, p=3E-06; SCZ:2p16.1
(VRK2): Stefansson – OR=1.09, p=3E-07
2p16.1-q11.2 D2S99 0.07683 0.01821 BP: 2p12 (CTNNA2): Scott -OR=1.2, p=3E-06; SCZ:2p16.1
(VRK2): Stefansson – OR=1.09, p=3E-07
3p25.3-p22.1 3.2 0.00994 0.00601 BP: 3p22.3 (NR): Ferreira - OR=1.18, p=4E-06; BP: 3p24.3 (2,
NR): Ferreira - OR=1.23, p=5E-06 & OR=1.15, p-5E-06; BP:
3p24.3 (RFTN1): Sklar - OR=0.79, p=3.47E-05; SCZ&BP (meta):
3p24.2 (NR): Wang-OR=1.28, p-1E-06)
5p13.3-q13.3 (3
window instances)
rs336081;
rs831818;
rs831791
3.63E-07** 3.63E-07**
5q14.3-q23.3 rs417670 4.62E-08** 4.61E-08** BP: 5q15 (MCTP1): Scott - OR=1.21, p=1E-07; SCZ&BP (meta):
5q21.3 (NR): Wang - OR=1.24, p=2E-06); SCZ: 5q21.1 (SLCO6A1):
Stefansson - 1.09, p=1E-06
6p23-p21.1 rs2064524 0.00050
1 0.00013
2 BP: 6p21 (NR): WTCCC - OR=1.19, p=4E-06; SCZ: 6p21.32 (MHC,
NOTCH): Stefansson - OR=1.19, p=2E-10; SCZ: 6p21.32(HLA-DQA1): Shi
- OR=1.14, p=7E-08; SCZ: 6p22.1 (2, NR): Shi- OR=1.28, p=1E-08 & ISC-
OR=1.22, p=1E-08); SCZ: 6p22.1 (MHC, PRSS16): Stefansson - OR=1.16,
p=1E-12
7pter-p21.1 7.1 0.05266 0.03724 SCZ&BP (meta): 7p22.3 (2, NR): Wang- OR=1.25, p=4E-06 &
OR=1.24, p=2E-06; BP: 7p21.1 (SP8): Lee-OR=1.44,p=5E-07
7q12.11-q31.1 7.4 0.04438 0.03032 BP&MDD: 7q21.12 (C7orf23, DMTF1): Liu - p=1E-06; SCZ:
7q22.1 (RELN): Shifman - OR=1.58, p=9E-07
8p11.21-q21.13 rs684872 0.02212 0.01304 SCZ&BP (meta): 8q12.1 (FAM110B):Wang - OR=1.56, p=2E-07
8q12.1-q22.1 rs1364616 0.02829 0.01688 SCZ&BP (meta): 8q12.1 (FAM110B):Wang - OR=1.56, p=2E-07
8q24.13-q24.3 D8S256 0.85627 0.03603 SCZ&BP (meta): 8q24.3 (NR):Wang - OR=1.56, p=2E-07
MSP: 10p11.21-q22.1;
GSMA (10.2): 10p14-
q11.21; GSMA(10.3):
10q11.21-q22.1 (see
p-values below)
rs1459990;
10.2
0.01274 0.01274 0.01723 0.01266 BP&MDD: 10q21.2 (ANK3): Liu – p=5E-07; BP: 10q21.2 (ANK3):
Ferreira - OR=1.45, p=9E-09; SCZ&BP (meta): 10q11.21 (NR):
Wang - OR=1.23, p=3E-06; SCZ: 10q21.2 (ANK3): Athanasiu -
OR=1.16, p=8E-06
MSP: 10q22.1-q24.1;
GSMA: 10q11.21-q22.1
rs2344769;
10.3
0.00389 0.00043
3 0.04708 0.03254 BP&MDD: 10q21.2 (ANK3): Liu – p=5E-07; BP: 10q21.2 (ANK3):
Ferreira - OR=1.45, p=9E-09; BP: 10q22.3 (NR): Ferreira -
OR=1.15, p=8E-06; SCZ&BP (meta): 10q11.21 (NR): Wang -
OR=1.23, p=3E-06; SCZ: 10q21.2 (ANK3): Athanasiu - OR=1.16,
p=8E-06
12q15-q23.2 12.4 0.04389 0.03093 BP: 12q21.1 (TSPAN8): Sklar - OR=0.58, p=6.11E-07
14q11.2-q13.1 rs1241620 6.02E-08** 6.02E-08** BP: 14q11.2 (NR): Ferreira - OR=1.3, p=5E-06; BP: 14q13.1
(NR): Ferreira - OR=1.59, p=5E-06; SCZ&BP (meta): 14q12 (2,
NR): Wang- OR=2.41, p-3E-06 & OR=1.23, p=2E-06;
SCZ,BP&MDD: 14q13.1 (NPAS3): Huang - p=4E-06
14q12-q22.3 rs2415438 0.00014 0.00014 BP: 14q13.1 (NR): Ferreira - OR=1.59, p=5E-06; SCZ,BP&MDD:
14q13.1 (NPAS3): Huang - p=4E-06
21q11.2-q21.3 rs12034 0.07500 0.04112
22q12.3-q13.33 rs1473953 0.01685 0.01685
**p,2.2E-05 (LK-significant).
*p,7.0E-04 (LK-suggestive).
p-values in bold font indicate at least nominal significance was reached.
GWAS overlap in bold font indicates the overlap was with bipolar GWAS.
doi:10.1371/journal.pone.0019073.t002
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coverage employed by GSMA, a substantial amount of chance
overlap between methods may have been expected. However, we
found minimal overlap for either disease. In fact, the vast majority
of regions significant by one method did not approach significance
by the other method. These findings are in keeping with the fact
that the methods are robust to different types of susceptibility loci
and, therefore, expected to be largely non-redundant. As we
expect distinct susceptibility architectures to emerge by different
genetic mechanisms and over different evolutionary timescales, we
may also expect that distinct types of susceptibility loci may,
largely, reside in separate genomic regions. This is consistent with
our findings.
The relative dominance of MSP findings over GSMA in both
disorders suggests that most linkage regions identified by our
analyses likely contain low frequency or rare susceptibility loci of
larger effect size while fewer contain relatively more common (i.e.,
low-frequency) loci of more modest effect. As most MSP regions
were not implicated by GSMA, the susceptibility loci residing in
these regions are likely uncommon or rare. And, to the extent that
the larger effect sizes necessary for MSP detection implicate higher
penetrance loci, substantial individual-level polygenicity would not
be necessary for disease expression for loci in these regions. Thus,
for the GWLS samples examined, the genetic architecture
suggested for both disorders is one dominated by heterogeneous
models, via the involvement of many low frequency or rare loci,
each relevant to a subset of affected families.
A proliferation of recent genetic investigations and reviews
suggest that multiple rare allelic and/or structural variants—and
therefore an architecture characterized by substantial locus and
allelic heterogeneity—may explain a substantial proportion of
susceptibility to major neuropsychiatric disorders [3,4,79,82,
83,84,85]. Furthermore, Cirulli & Goldstein (2010) [4] note that
the diversity of linkage regions implicated across different families
securely confirms high locus heterogeneity for many common
diseases. In fact, their review of genetic results over the past several
Table 3. Linkage Meta-Analyses Results for Schizophrenia.
p-values
ChrBAND for
MSP Window/
GSMA Bin
Midpoint
Marker/
Bin #
MSP
single
MSP
best
GSMA
narrow
GSMA
broad
Schizophrenia (SCZ) GWAS, Bipolar Disorder (BP) GWAS and GWAS
Meta-Analysis (meta) Overlap
1p13.1-q24.1
# D1S1653 0.49120 0.00505
1q21.3-q24.3
# D1S1679 0.78591 0.00233
1q21.3-q25.1 D1S1677 0.76803 0.00209
1q23.2-q25.3 D1S196 0.75513 0.00194
2p25.1-p23.2 2.2 0.02161 0.01552 SCZ&BP (meta): 2p24.3 (NR): Wang - OR=1.37, p=4E-06
2p12-q22.1 2.5 0.03488 0.01497 SCZ&BP (meta): 2q21.2 (NAP5): Wang - OR=1.39, p=7E-07; BP: 2p12
(CTNNA2): Scott - OR=1.2, p=3E-06 ; BP: 2q11.2 (intergenic): Scott - OR=1.17,
p=3E-06; BP: 2q11.2 (intergenic): Ferreira - OR=1.17, p=3E-06
2q36.1-q37.3 D2S427 0.46951 0.01064 BP: 2q37.3 (NR): WTCCC - OR=1.84, p=7E-06
2q36.3-q37.3 D2S345 0.53986 0.00860 BP: 2q37.3 (NR): WTCCC - OR=1.84, p=7E-06
3p14.1-q12.3 3.4 0.03722 0.21419
3q12.3-q22.1 3.5 0.01405 0.04055
4p14-q13.3 4.3 0.04692 0.03987 BP: 4q12 (KIT): Scott- OR=1.16, p=4E-06
5p14.3-q11.2 D5S1470 0.83170 0.02874
5p14.2-q11.2
# D5S426 0.83170 0.02989
5q31.3-q34 D5S820 0.65163 0.01176 SCZ&BP (meta): 5q33.3 (NR): Wang - OR=1.56, p=1E-06
5q32-q35.1 D5S422 0.67042 0.01599 SCZ&BP (meta): 5q33.3 (NR): Wang - OR=1.56, p=1E-06
MSP: 6q22.31-q24.3;
GSMA: 6q23.2-q25.3
D6S292; 6.5 0.92453 0.02617 0.03742 0.02070 BP&MDD: 6q25.2 (SYNE1): Liu - p=1E-06; BP: 6q25.2 (NR): Ferreira - OR=1.22,
p=4E-06
6q25.3-qter 6.6 0.00267 0.01106
8p23.1-p21.1 D8S1145 0.44879 0.01525 SCZ&BP (meta): 8p21.3 (NR): Wang - OR=1.34, p=4E-06
8p23.1-p12 D8S560 0.38511 0.01849 SCZ&BP (meta): 8p21.3 (NR): Wang - OR=1.34, p=4E-06; BP: 8p12 (NR):
Scott - OR=1.33, p=6E-06
8p22-p12 D8S136 0.38511 0.01849 SCZ&BP (meta): 8p21.3 (NR): Wang - OR=1.34, p=4E-06; BP: 8p12 (NR):
Scott - OR=1.33, p=6E-06
8p22-p11.21
# D8S1771 0.36015 0.01632 SCZ&BP (meta): 8p21.3 (NR): Wang - OR=1.34, p=4E-06; BP: 8p12 (NR):
Scott - OR=1.33, p=6E-06
8p21.3-q12.1 D8S1477 0.21596 0.00678 SCZ&BP (meta): 8p21.3 (NR): Wang - OR=1.34, p=4E-06; SCZ&BP
(meta): 8q12.1 (FAM110B): Wang - OR=1.56, p=2E-07; BP: 8p12 (NR):
Scott - OR=1.33, p=6E-06
#indicates two MSP window instances occurred.
p-values in bold font indicate at least nominal significance was reached.
GWAS overlap in bold font indicates the overlap was with schizophrenia GWAS.
doi:10.1371/journal.pone.0019073.t003
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to Mendelian diseases than is postulated by the common disease-
common variant model.
Diagnostic Models Implicated Across Meta-Analytic
Methods
Interestingly, our MSP-Best analysis consistently produced
stronger results than MSP-Single for both disorders. In the case
of schizophrenia, in fact, all significant results were found under
MSP-Best analysis only. This suggests that the regions implicated
by MSP may be more likely to mediate risk for narrower
diagnostic models tested across GWLS. For the GSMA analyses,
the best-fitting models differed somewhat across disorders. For
bipolar disorder, GSMA-Broad produced consistently stronger
results than the GSMA-Best model; for schizophrenia, significance
was split between GSMA-Broad (4 bins) and GSMA-Best (3 bins).
Thus, across disorders, regions implicated by GSMA may be more
likely to harbor loci contributing to risk for the broadest
phenotypic characteristics. Again, this is consistent with our
architectural hypotheses. We generally expect the most clearly
defined phenotypes to be the most highly-penetrant and, therefore,
more detectable by MSP. On the other hand, loci mediating
broader phenotypic characteristics are expected to be less
penetrant, perhaps representing common, modifier genes, best
detected through GSMA.
Comparative Linkage Meta-Analysis: Overlap with
Previous Association Evidence
Short of fine mapping or, ultimately, deep sequencing of regions
implicated by each method, further evidence for the architectural
implications proposed here may be sought in the extant genetic
literature. If differential evidence from MSP and GSMA implicates
distinct genetic architectures, we may expect differences in the
consistency of candidate gene association evidence within the
regions implicated under each method (See File S1 for further
discussion.) That said, candidate gene selection is subjective and
not genomewide in scope, so such studies are certainly insufficient
as a means of verifying linkage meta-analytic findings. Thus,
comparison with previous GWAS findings may be most useful.
As noted in the introduction, GWAS are expected to identify
regions likely to harbor common variants of modest effect. More
specifically, under standard design and interpretation of GWAS
methods, disease-associated GWAS SNPs are expected to be in
linkage disequilibrium (LD) with, and therefore in relatively close
proximity to, the putative common, functional variant. This
generally accepted interpretation, however, has at least three
caveats that may be relevant when comparing GWAS findings to
linkage meta-analysis. First, the correlation between the strength of
GWAS association signals and the extent of actual disease
association at the risk locus will depend on the allele frequency
of the relevant variant, degree of LD with the incorporated marker
and the power of the study. Thus, modest GWAS evidence could
implicate moderately-common loci and/or moderately-large effect
sizes at the actual risk locus. Under these circumstances, we might
expect to find regional overlap between GSMA and GWAS
findings.
There are also at least two situations in which low-frequency
or rare loci of relatively large effect may produce significant
GWAS signals. The first would be chance oversampling of cases
with the same uncommon pathogenic locus (e.g., latent family
substructure). Under such circumstances, considerable inconsis-
tencies between independent GWAS would be expected and
overlap with MSP would be possible, but not predictable. The
second, and perhaps more likely, situation would be cases in
which signals at common SNPs were produced by ‘synthetic’
effects at multiple rare loci. As most recently discussed by
Dickson, et al (2010) [86] ‘‘variants much less common than the
associated one may create ‘synthetic associations’ by occurring,
stochastically, more often in association with one of the alleles at
the common site versus the other allele.’’ (p. 1) The authors
systematically explore this possibility, through simulated and real
GWAS data, and conclude that such synthetic associations, when
present, are likely to represent effects across extremely large (i.e.,
2.5 Mb) genomic intervals. Thus, if GWAS signals are
attributable to such synthetic associations, we might expect
overlap with MSP findings.
Regions implicated by MSP only: GWAS overlap
Given the methodologic distinctions between MSP and GSMA,
regions implicated by MSP only suggest the presence of one or
more loci that are uncommon or rare in the sampled populations
and of relatively large effect. Under standard assumptions of
GWAS study design, we would also expect that such loci would
not produce positive evidence of association in GWAS studies. In
light of the above-noted caveats to standard GWAS interpretation,
however, regions implicated by both MSP and GWAS (assuming
both findings are true positives), in the absence of positive GSMA
findings, have at least two alternative explanations. First, the
regions may be implicated by both methods due to independent
effects of two distinct types of loci within the region–both rare loci
of large effect (+MSP) and other common, loci of modest effect
(+GWAS). Second, the regions may be implicated by both
methods non-independently—that is, a single locus or proximal
cluster of loci that are uncommon to rare and of relatively large
effect are creating both linkage and association signals (the latter
via the mechanism as described above [86]).
Bipolar Disorder. Although overlap between GSMA with
GWAS was found more consistently in bipolar disorder, there is
still substantial overlap between MSP-only regions and previous
GWAS findings. Additionally, other than the 5p13.3-q13.3
window, which met LK-significance criteria and did not contain
a GWAS associated SNP, there appeared to be a general trend for
regions with stronger MSP evidence to be more likely to overlap
with previous GWAS evidence. If MSP-GWAS overlap is due
primarily to independent effects at distinct locus types, then we
might not expect to observe a relationship between the strength of
MSP findings and the likelihood of GWAS findings. On the other
hand, if the overlap is due primarily, or at least partially, to
synthetic associations of rare variants, then we might predict
regions with stronger MSP signals to be more likely to also contain
GWAS associations, which is largely consistent with our results.
The resolution of the mechanisms underlying such colocalization
must await further genetic and functional analyses, but raises
interesting questions about the architectures represented within
regions of MSP-GWAS overlap.
Schizophrenia. Our finding of less MSP-GWAS overlap for
schizophrenia, relative to that found in bipolar, may be somewhat
surprising if only because there are more published reports of
GWAS in schizophrenia than in bipolar. Three additional factors
may contribute to this finding. First, smaller average population
sample sizes used in schizophrenia GWAS to date will reduce
power to detect association and likely contributed to the lower
reported number of SNP associations for schizophrenia ([78],
accessed 11/27/10). Second, the likelihood of finding GWAS
overlap in schizophrenia may have been reduced by the fact
that the schizophrenia GWAS samples were primarily of
European ancestry, while the ethnic composition of the included
Meta-Analysis and Genetic Architectures
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further discussion of GWAS and GWLS characteristics).
Third, a substantial recent literature suggests that the genetic
architecture of schizophrenia may be characterized by more
pronounced genetic heterogeneity (via both single nucleotide and
copy number variations) and contributions from rare variants
[4,26,37,38,87,88]. As noted above, GWAS is not expected to be
especially robust under such an architecture. In addition, the
degree to which synthetic associations of rare variants are
detectable by tag SNPs used in GWAS will also depend on the
MAF of the causal alleles. As demonstrated by Wang, et al (2010)
[89] in their analyses of simulated and real datasets, tag SNPs
significantly underestimate the true effect sizes of causal alleles and
the degree of expected underestimation increases with decreasing
causal MAF. Thus, regions containing only very rare causal
variants are unlikely to produce GWAS signals that reach even
nominal significance thresholds for reporting.
Regions Implicated by GSMA only: GWAS overlap
Given the two alternative mechanisms by which GSMA bin
significance can arise (see Introduction), the specific architectural
implications of GSMA-only findings may be further refined by
considering the presence (vs. absence) of co-localized GWAS
findings. GSMA-only signals that overlap with positive GWAS
evidence are more likely to result via the single locus mechanism,
and suggest a regional architecture contributing to polygenic
models. In other words, a single common locus will contribute
modestly to the disease risk and, thereby, require the simultaneous
effects of other loci (i.e., polygenicity) for disease expression.
GSMA-GWAS overlap was found in 100% of bipolar GSMA-only
bins and 33% of schizophrenia GSMA-only bins.) Moreover, in
schizophrenia, GSMA-GWAS overlap was produced only by the
most recent combined bipolar-schizophrenia meta-analysis [21].
GSMA-only regions without co-localized GWAS evidence may
be more likely to harbor low-frequency loci of ‘moderate’ effect
(i.e., variant frequencies below the GWAS detection threshold and
variant penetrances below the MSP threshold.) In addition to the
possible architectural causes, less frequent GSMA-GWAS overlap
in schizophrenia may also result from the missing marker data for
many of our included GWLS, ethnic differences between samples,
or low power of the schizophrenia GWAS to date.
Regions Implicated by both MSP & GSMA: GWAS Overlap
The regional colocalization of GSMA and MSP evidence
suggests either the presence of an admixture of locus types (i.e.,
some low-frequency/moderate effect, others rare/strong effect) or
of loci that are relatively common and relatively large in effect.
Bipolar Disorder. Though the two MSP windows that
overlapped with significant GSMA bins were not among the
bipolar windows meeting LK-significance or -suggestive criterion,
their significance under both MSP models (broad and narrow),
their overlap with two adjacent GSMA bins and the presence of
GWAS SNP association evidence therein provides a strong
complement of evidence for the localization of at least one
strongly disease-linked variant. Moreover, the fact that a bipolar
GWAS [15], a bipolar GWAS meta-analysis [11], a combined
bipolar and MDD GWAS [20] and the recent combined GWAS
meta-analysis [21] found evidence for association within the ANK3
gene suggests that this gene is very likely among the contributors to
the linkage signals. Though the convergence of MSP, GSMA and
GWAS data may suggest the presence of a single, common locus
of relatively large effect size, there is also evidence to support an
alternate architecture at this locus.
First, at least three different SNP markers (rs9804190 [8],
rs1094336 [11], and rs109433 [20]) have been implicated across
bipolar (or combined) GWAS and GWAS meta-analyses, making
a single common variant somewhat less unlikely. Additionally,
Schulze, et al (2008) [90] performed an association analysis of two
ANK3 markers (rs9804190 and rs1094336) across three indepen-
dent samples and found strong evidence supporting ANK3 as a
bipolar susceptibility locus with true, independent allelic hetero-
geneity; their data did not support an interacting model at these
two alleles. Given our significant MSP findings in this region, and
the fact that linkage is robust to allelic heterogeneity, the low
GWAS odds ratio (OR) estimates for the ANK3 gene most likely
derive from the fact that genotyped tag SNPs in GWAS studies are
not the actual functional variants mediating disease risk and are
likely not in complete LD with the true variant(s). Additionally, the
population-based design of GWAS will produce low OR estimates
if disease in only a small portion of the sampled population is
mediated by this locus, even if the functional variant were
genotyped. Hence, the ORs produced by GWAS are unlikely to
represent the true effect sizes of the functional variant(s) which are
only approximated, in both location and effect, by the tagSNPs
genotyped in GWAS [4,89].
Schizophrenia. One significant MSP window (6q22.31-
q24.3) overlapped with a significant GSMA bin (6q23.2-q25.3),
creating one distinct region of MSP-GSMA overlap: 6q23.2-q24.3.
Although neither the MSP window nor the GSMA bin reached
LK evidence criteria, the likelihood that the GSMA results
represent false positives are diminished by the fact that bin 6.6,
adjacent to the overlapping bin 6.5, was also significant. Together,
these findings provide a strong complement of evidence for the
localization of at least one variant strongly-linked to schizophrenia.
Further characterization of the true functional variant and follow-
up family and population-based studies will clarify the best
architectural model befitting this linked region.
Conclusions
Our meta-analyses produced nominal evidence of linkage for
bipolar disorder and schizophrenia in several genomic regions.
While only windows in the bipolar MSP analysis produced
evidence meeting the stringent LK-significance (3 windows) or
LK-suggestive (5 windows) criteria, several other aspects of our
results lend weight to our nominally-significant regions. First, we
expect our results to be conservative given the likely neutralizing
effects of missing data in both GSMA and MSP analyses, as
suggested by comparison of full to RED bipolar analysis results in
both GSMA and MSP. Second, in both bipolar disorder and
schizophrenia, adjacent pairs of bins were implicated by GSMA.
As noted by previous authors [45], such results are less likely to
represent false positives. Third, for many of the regions implicated
in our bipolar analyses (and for some implicated in the
schizophrenia analyses), we found previous evidence of SNP
associations from GWAS in the respective disorder. Fourth, from
even a cursory review of the candidate gene literature [91], it is
apparent that genes in many of our implicated regions have
previous association evidence. (See File S1 for further discussion of
genes within implicated regions).
Our most interesting finding is that our analysis of an identical
set of marker results implicated almost entirely distinct genomic
regions under the two methods. As MSP is most robust to the
identification of relatively rare loci of strong effect, we expect that
the regions implicated by positive findings in MSP only are most
likely to harbor a genetic architecture most befitting models of
genetic heterogeneity. As GSMA is most robust to the detection of
genomic bins that most consistently harbor disease-related locus(i)
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findings on GSMA only will be more likely to contain loci befitting
polygenic, interacting models. Furthermore, we found a greater
number of significant MSP windows than GSMA bins, suggesting
that a greater number of genomic regions are likely to mediate
heterogeneous architectural models while fewer are likely to
mediate polygenic risk architecture.
Future Directions
Despite strong heritability, further large scale linkage studies are
unlikely to be completed given the costs of ascertaining large
numbers of families and the failure of results to converge
convincingly to date. Discussion abounds in the literature as to
the most appropriate direction for current and upcoming genetic
investigations. Some have advocated larger GWAS (i.e., with tens
of thousands of cases and controls) in order to map the common
variants with very small effect sizes. Advocates on the other end of
the variant frequency spectrum propose the use of whole genome
sequencing as the ultimate, model-free method to identify rare,
highly-penetrant, functional variants. Approaches in between the
extremes include: candidate gene and regulatory region sequenc-
ing, population-based approaches to linkage analysis using IBD
sharing [92], using long-range haplotype phasing to select cases for
sequencing near tagSNPs [86,89], targeted re-sequencing under
linkage peaks [79] and whole-exome sequencing [4]. While whole
genome sequencing will soon be both feasible and affordable, the
analytic burden inherent to such data may far outweigh its
potential to yield meaningful discovery until further progress is
made in understanding more basic aspects of risk architecture and
the likely pathophysiology of these complex disorders. Interesting-
ly, our finding may suggest that results from comparative linkage
meta-analyses (CLMA) of extant data may serve to guide selection
of the most appropriate type of follow-up analyses. For example, if
regions mediating a heterogeneous architecture are consistently
implicated across large portions of the genome, a bioinformati-
cally-informed, whole-exome sequencing approach (e.g., one using
dimensionality reduction based on genomic conservation, gene
ontology or pathway involvement to prioritize likely functional
variants) may be optimal for identification of rare functional
variants. On the other hand, if regions likely to mediate polygenic
architecture are relatively confined, denser SNP arrays and/or
more targeted sequencing may be indicated.
Our analysis represents a pilot investigation to explore the use of
complementary meta-analysis to illuminate genetic architecture in
complex neuropsychiatric disorders. As suggested by the present
results, this approach may help to prioritize regions for further
analysis, depending upon the objectives of the investigators. While
the identification of loci contributing modestly to population-level
risk may be of greater epidemiologic relevance (i.e., contribute
more to population attributable risk), the identification of disease-
associated rare variants, which are much more likely to be
functional, will be more helpful in elucidating underlying
pathophysiological mechanisms. For these reasons, we would
encourage research collaboratives and consortia with access to
large numbers of full GWLS results to conduct comparative
linkage meta-analyses on their own troves of linkage data.
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